Compare Norfolk Southern Corporation (NSC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Norfolk Southern Corporation trades at $326.37 (market cap $72.13B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Norfolk Southern Corporation is far larger — about 9.6× Spyre Therapeutics Inc. Common Stock's market cap, and Norfolk Southern Corporation pays a 1.68% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 34 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NSC | SYRE | |
|---|---|---|
Market Cap | $72.13B | $7.52B |
Volume | 650,750 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $352.98 | $108.92 |
52-Week Low | $278.19 | $22.18 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $87.68B | $6.52B |
Dividend Yield | 1.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $321.14, up 0.56% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (21.02% net margin). Recent news highlights momentum for the Union Pacific merger, while institutional buying and a $361.86 consensus price target suggest upside potential.
Outlook remains positive with merger progress and dividend stability, but risks include fuel cost pressures and regulatory hurdles. The current valuation (P/E 27.4) demands execution on freight share gains and merger benefits to justify further gains.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
